Dr. Shah Discusses Sequencing for MCL

Bijal D. Shah, MD
Published: Friday, Nov 17, 2017



Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).

Sequencing will play a role in determining which treatments to give to patients with MCL. According to Shah, clinically, a patient with a p53 mutation should first receive lenalidomide (Revlimid).

The next big biomarker will be the ColonoSEQTM minimal residual disease (MRD) approach to assess death of remission, explains Shah.
 


Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).

Sequencing will play a role in determining which treatments to give to patients with MCL. According to Shah, clinically, a patient with a p53 mutation should first receive lenalidomide (Revlimid).

The next big biomarker will be the ColonoSEQTM minimal residual disease (MRD) approach to assess death of remission, explains Shah.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x